Search

Your search keyword '"Nirenberg, Melissa J."' showing total 222 results
Start Over Author "Nirenberg, Melissa J."
222 results on '"Nirenberg, Melissa J."'

1. Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Author

Farrell, Kurt, Humphrey, Jack, Chang, Timothy, Zhao, Yi, Leung, Yuk Yee, Kuksa, Pavel P., Patil, Vishakha, Lee, Wan-Ping, Kuzma, Amanda B., Valladares, Otto, Cantwell, Laura B., Wang, Hui, Ravi, Ashvin, De Sanctis, Claudia, Han, Natalia, Christie, Thomas D., Afzal, Robina, Kandoi, Shrishtee, Whitney, Kristen, Krassner, Margaret M., Ressler, Hadley, Kim, SoongHo, Dangoor, Diana, Iida, Megan A., Casella, Alicia, Walker, Ruth H., Nirenberg, Melissa J., Renton, Alan E., Babrowicz, Bergan, Coppola, Giovanni, Raj, Towfique, Höglinger, Günter U., Müller, Ulrich, Golbe, Lawrence I., Morris, Huw R., Hardy, John, Revesz, Tamas, Warner, Tom T., Jaunmuktane, Zane, Mok, Kin Y., Rademakers, Rosa, Dickson, Dennis W., Ross, Owen A., Wang, Li-San, Goate, Alison, Schellenberg, Gerard, Geschwind, Daniel H., Crary, John F., and Naj, Adam

Published
2024
Full Text
View/download PDF

2. Single-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy

Author

Whitney, Kristen, primary, Song, Won-Min, additional, Sharma, Abhijeet, additional, Dangoor, Diana K., additional, Farrell, Kurt, additional, Krassner, Margaret M., additional, Ressler, Hadley W., additional, Christie, Thomas D., additional, Walker, Ruth H., additional, Nirenberg, Melissa J., additional, Zhang, Bin, additional, Frucht, Steven J., additional, Riboldi, Giulietta M, additional, Crary, John F., additional, and Pereira, Ana C., additional

Published
2023
Full Text
View/download PDF

4. Minor Phenomena in Parkinson's Disease–Prevalence, Associations, and Risk of Developing Psychosis.

Author

Schneider, Ruth B., Auinger, Peggy, Dobkin, Roseanne D., Mills, Kelly A., Kulick-Soper, Catherine V., Myers, Taylor L., Korell, Monica, Pontone, Gregory M., and Nirenberg, Melissa J.

Subjects
APATHY, PARKINSON'S disease, MOVEMENT disorders, PSYCHOSES, RAPID eye movement sleep, SLEEP disorders
Abstract

Background: Minor phenomena, including passage phenomena, feeling of presence, and illusions, are common and may represent a prodromal form of psychosis in Parkinson's disease (PD). We examined the prevalence and clinical correlates of minor phenomena, and their potential role as a risk factor for PD psychosis. Methods: A novel questionnaire, the Psychosis and Mild Perceptual Disturbances Questionnaire for PD (PMPDQ), was completed by Fox Insight cohort participants with and without PD. Additional assessments included the Non-Motor Symptoms Questionnaire (NMSQuest), REM Sleep Behavior Disorder Single Question Screen (RBD1Q), Movement Disorder Society-Unified Parkinson Disease Rating Scale Part II, demographic features, and medication usage. For participants with PD, we used regression models to identify clinical associations and predictors of incident psychosis over one year of follow-up. Results: Among participants with PD (n = 5950) and without PD (n = 1879), the prevalence of minor phenomena was 43.1% and 31.7% (P <.001). Of the 3760 participants with PD and no baseline psychosis, independent correlates of minor phenomena included positive responses on the NMSQuest apathy/attention/memory (OR 1.7, 95% CI 1.3-2.1, P <.001) or sexual function domain (OR 1.3, 95% CI 1.1-1.6, P =.01) and positive RBD1Q (OR 1.3, 95% CI 1.05-1.5, P =.01). Independent risk factors for incident PD psychosis included the presence of minor phenomena (HR 3.0, 95% CI 2.4-3.9, P <.001), positive response on the NMSQuest apathy/attention/memory domain (HR 1.8, 95% CI 1.3-2.6, P <.001), and positive RBD1Q (HR 1.5, 95% CI 1.1-1.9, P =.004). Conclusions: Minor phenomena are common, associated with specific non-motor symptoms, and an independent predictor of incident psychosis in PD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. An Autopsy Series of Seven Cases of VPS13A Disease (Chorea‐Acanthocytosis)

Author

Ditzel, Ricky M., primary, Walker, Ruth H., additional, Nirenberg, Melissa J., additional, Tetlow, Amber M., additional, Farrell, Kurt, additional, Lind‐Watson, Kourtni J., additional, Thorn, Emma L., additional, Dangoor, Diana K., additional, Gordon, Ronald, additional, De Sanctis, Claudia, additional, Barton, Brandon, additional, Karp, Barbara I., additional, Kirby, Alana, additional, Lett, Debra J., additional, Mente, Karin, additional, Simon, David K., additional, Velayos‐Baeza, Antonio, additional, Miltenberger‐Miltenyi, Gabriel, additional, Humphrey, Jack, additional, and Crary, John F., additional

Published
2023
Full Text
View/download PDF

10. Dystonic Storm

Author

Nirenberg, Melissa J., Ford, Blair, Tarsy, Daniel, editor, Frucht, Steven J., and Fahn, Stanley

Published
2005
Full Text
View/download PDF

12. A MDS Evidence-Based Review on Treatments for Huntington's Disease

Author

Ferreira, Joaquim J, Rodrigues, Filipe B, Duarte, Gon��alo S, Mestre, Tiago A, Bachoud-Levi, Anne-Catherine, Bentivoglio, Anna Rita, Burgunder, Jean-Marc, Cardoso, Francisco, Claassen, Daniel O, Landwehrmeyer, G Bernard, Kulisevsky, Jaime, Nirenberg, Melissa J, Rosser, Anne, Roth, Jan, Seppi, Klaus, Slawek, Jaroslaw, Furr-Stimming, Erin, Tabrizi, Sarah J, Walker, Francis O, Vandenberghe, Wim, Costa, Jo��o, and Sampaio, Cristina

Subjects
610 Medicine & health
Abstract

BACKGROUND Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. Its management is challenging, consisting mainly of off-label treatments. OBJECTIVES The International Parkinson and Movement Disorder Society commissioned a task force to review and evaluate the evidence of available therapies for HD gene expansion carriers. METHODS We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Eligible randomized controlled trials were identified via an electronic search of the CENTRAL, MEDLINE, and EMBASE databases. All eligible trials that evaluated one or more of 33 predetermined clinical questions were included. Risk of bias was evaluated using the Cochrane Risk of Bias tool. A framework was adapted to allow for efficacy and safety conclusions to be drawn from the balance between the GRADE level of evidence and the importance of the benefit/harm of the intervention. RESULTS Twenty-two eligible studies involving 17 interventions were included, providing data to address 8 clinical questions. These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea. The data did not support a disease-modifying effect for premanifest and manifest HD. There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality. Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments. CONCLUSIONS Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms. �� 2021 International Parkinson and Movement Disorder Society.

Published
2022
Full Text
View/download PDF

15. An MDS Evidence‐Based Review on Treatments for Huntington's Disease

Author

Ferreira, Joaquim J., primary, Rodrigues, Filipe B., additional, Duarte, Gonçalo S., additional, Mestre, Tiago A., additional, Bachoud‐Levi, Anne‐Catherine, additional, Bentivoglio, Anna Rita, additional, Burgunder, Jean‐Marc, additional, Cardoso, Francisco, additional, Claassen, Daniel O., additional, Landwehrmeyer, G. Bernard, additional, Kulisevsky, Jaime, additional, Nirenberg, Melissa J., additional, Rosser, Anne, additional, Roth, Jan, additional, Seppi, Klaus, additional, Slawek, Jaroslaw, additional, Furr‐Stimming, Erin, additional, Tabrizi, Sarah J., additional, Walker, Francis O., additional, Vandenberghe, Wim, additional, Costa, João, additional, and Sampaio, Cristina, additional

Published
2021
Full Text
View/download PDF

36. An MDS Evidence‐Based Review on Treatments for Huntington's Disease.

Author

Ferreira, Joaquim J., Rodrigues, Filipe B., Duarte, Gonçalo S., Mestre, Tiago A., Bachoud‐Levi, Anne‐Catherine, Bentivoglio, Anna Rita, Burgunder, Jean‐Marc, Cardoso, Francisco, Claassen, Daniel O., Landwehrmeyer, G. Bernard, Kulisevsky, Jaime, Nirenberg, Melissa J., Rosser, Anne, Roth, Jan, Seppi, Klaus, Slawek, Jaroslaw, Furr‐Stimming, Erin, Tabrizi, Sarah J., Walker, Francis O., and Vandenberghe, Wim

Abstract

Background: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. Its management is challenging, consisting mainly of off‐label treatments. Objectives: The International Parkinson and Movement Disorder Society commissioned a task force to review and evaluate the evidence of available therapies for HD gene expansion carriers. Methods: We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Eligible randomized controlled trials were identified via an electronic search of the CENTRAL, MEDLINE, and EMBASE databases. All eligible trials that evaluated one or more of 33 predetermined clinical questions were included. Risk of bias was evaluated using the Cochrane Risk of Bias tool. A framework was adapted to allow for efficacy and safety conclusions to be drawn from the balance between the GRADE level of evidence and the importance of the benefit/harm of the intervention. Results: Twenty‐two eligible studies involving 17 interventions were included, providing data to address 8 clinical questions. These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea. The data did not support a disease‐modifying effect for premanifest and manifest HD. There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality. Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments. Conclusions: Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms. © 2021 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Impulse Control Disorders in Parkinson's Disease: Too Much of a Good Thing?

Author

Nirenberg, Melissa J.

Subjects
Impulsive personality -- Causes of, Parkinson's disease -- Complications and side effects, Parkinson's disease -- Drug therapy, Dopamine -- Agonists, Dopamine -- Complications and side effects, Health
Abstract

Impulse Control Disorders in Parkinson's Disease: Too Much of a Good Thing? Abstract & Commentary By Melissa J. Nirenberg, MD, PhD, Assistant Professor, Neurology and Neuroscience, Weill Cornell Medical College. [...]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results